Jacqueline Achkar is a physician scientist specialised in Infectious Diseases with an additional Master of Science Degree in Clinical Research Methods. She is currently an Associate Professor of Medicine in the Departments of Medicine (Division of Infectious Diseases), and Microbiology and Immunology at the Albert Einstein College of Medicine in New York, US. She is further the Co-Director of Einstein's Global Health Center, and the Associate Director for the Translational Research Track of Einstein's Clinical Research Training Program (CRTP), a Master's programme with the mission of training clinician scientists towards a successful career as independent clinical and translational investigators. Achkar has built a well-established and successful translational research programme in the fields of tuberculosis serology, biomarker discovery, and protective immune responses to tuberculosis. Active tuberculosis (TB) remains a global public health problem, and TB ranks alongside with HIV as the leading cause of death worldwide. Early diagnosis, treatment, and prevention of TB are the cornerstones for disease control. Despite the worldwide implementation of a new a nucleic acid amplification based tests (GeneXpert) which has improved rapid TB diagnosis considerably, the need for simple point-of-care diagnostics, such as dipstick tests, remains high in many resource-limited settings, especially those with high HIV prevalence. Achkar's work is focused on the evaluation of host responses to M. tuberculosis in patients at various states of infection, including HIV co-infection, towards i) the detection of biomarker with the potential to inform the development of simple, rapid diagnostic tests for TB; and ii) the identification and study of antibody responses that correlate with the protection against TB which could inform TB vaccine development strategies. She has multiple long-standing successful national and international collaborations with clinicians and scientists from various fields, including several investigators in South Africa.